Wednesday, July 8, 2026

pharma · Melanoma · Ovarian Cancer

Sandoz (Japan)

Sandoz (Japan) clinical programs — 2 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Basel, CH HQ
17,495 Employees
TGA registrant Type
Company details
Status
Public
HQ
Basel, CH
Employees
17,495
Programs
4
Drugs
22
Patents
0
Intelligence · Clinical Programs

Sandoz (Japan) projects

2 ClinicalTrials.gov programs sponsored by Sandoz (Japan).

Sandoz (Japan) has 2 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. GME751

    Sandoz Pty Ltd

    Melanoma

    phase 1 small molecule active

    1 trial
  2. Olaparib tablets, 150 mg

    Sandoz Pty Ltd

    Ovarian Cancer

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Sandoz (Japan) have?

2 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.